Trial Nickname: ATLAS-2M

Full Name: Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

Participant Overview: This study will divide subjects into two groups. Group 1 will include subjects receiving current ART standard of care therapy, Group 2 will include subjects currently receiving long-acting cabotegravir (CAB LA) and long-acting rilpivirine (RPV LA) in the current ATLAS study. Both groups will be randomized to receive CAB LA + RPV LA in either four-week or eight-week intervals.

Major Eligibility Criteria:
•At least 18 years old
•Currently suppressed viral load for longer than 6 months on the first treatment regimen

This study will evaluate the safety and effectiveness of switching to long-acting cabotegravir (CAB LA) and long-acting rilpivirine (RPV LA) administered every eight weeks compared to CAB LA + RPV LA administered every four weeks (Q4W) over a 48-week treatment period in approximately 1,020 adult HIV-1 infected subjects. Participants will receive injections of the medication every four or eight weeks onsite at CRI’s research facility in Boston.

Study Sponsor: ViiV Healthcare

For more information, please contact: Our Research Team, 617.502.1707 or

*Please note this Clinical Trial and Summary was started while Community Research Initiative was still known as Community Research Initiative (CRI). This information is still relevant.

ATLAS 2M Web Summary PDF

Contact our Research Team